Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
This Govt. Act Can Help Investors (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
This Govt. Act Can Help Investors (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
This Govt. Act Can Help Investors (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
This Govt. Act Can Help Investors (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
NYSE:GKOS

Glaukos - GKOS Stock Forecast, Price & News

$46.46
-0.67 (-1.42%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$46.31
$47.28
50-Day Range
$46.46
$57.75
52-Week Range
$33.33
$64.49
Volume
258,204 shs
Average Volume
406,570 shs
Market Capitalization
$2.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.13

Glaukos MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
29.4% Upside
$60.13 Price Target
Short Interest
Bearish
8.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.17mentions of Glaukos in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.20) to ($1.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

501st out of 1,038 stocks

Surgical & Medical Instruments Industry

56th out of 103 stocks

GKOS stock logo

About Glaukos (NYSE:GKOS) Stock

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Stock News Headlines

Glaukos (NYSE:GKOS) Downgraded to Sell at StockNews.com
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
See More Headlines
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Company Calendar

Last Earnings
11/02/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
727
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$60.13
High Stock Price Forecast
$69.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+29.4%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$-49,590,000.00
Pretax Margin
-31.42%

Debt

Sales & Book Value

Annual Sales
$294.01 million
Book Value
$12.52 per share

Miscellaneous

Free Float
43,839,000
Market Cap
$2.22 billion
Optionable
Optionable
Beta
1.26

Key Executives

  • Mr. Thomas William Burns (Age 61)
    Chairman & CEO
    Comp: $1.96M
  • Mr. Joseph E. GilliamMr. Joseph E. Gilliam (Age 45)
    Pres & COO
    Comp: $991.52k
  • Mr. Chris M. Calcaterra (Age 62)
    Exec. VP of Global Commercial Operations
    Comp: $1M
  • Dr. Mory Gharib Ph.D.
    Co-Founder
  • Mr. Alex R. Thurman (Age 52)
    Sr. VP & CFO
  • Mr. Christopher William Lewis
    VP of Investor Relations & Corp. Affairs
  • Ms. Diane W. Biagianti (Age 62)
    Sr. VP & Gen. Counsel
  • Ms. Diana A. Scherer
    VP of Compliance & Deputy Gen. Counsel
  • Ms. Michele M. Allegretto
    Sr. VP of HR
  • Mr. David S. Haffner
    Sr. VP of New Technologies













GKOS Stock - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GKOS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View GKOS analyst ratings
or view top-rated stocks.

What is Glaukos' stock price forecast for 2023?

9 brokers have issued 12-month price targets for Glaukos' stock. Their GKOS share price forecasts range from $48.00 to $69.00. On average, they predict the company's stock price to reach $60.13 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price.
View analysts price targets for GKOS
or view top-rated stocks among Wall Street analysts.

How have GKOS shares performed in 2022?

Glaukos' stock was trading at $44.44 at the beginning of 2022. Since then, GKOS shares have increased by 4.5% and is now trading at $46.46.
View the best growth stocks for 2022 here
.

Are investors shorting Glaukos?

Glaukos saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 4,160,000 shares, an increase of 5.3% from the September 30th total of 3,950,000 shares. Based on an average trading volume of 539,200 shares, the short-interest ratio is currently 7.7 days. Approximately 9.1% of the company's shares are short sold.
View Glaukos' Short Interest
.

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our GKOS earnings forecast
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) released its quarterly earnings data on Wednesday, November, 2nd. The medical instruments supplier reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.08. The medical instruments supplier had revenue of $71.27 million for the quarter, compared to analysts' expectations of $67.88 million. Glaukos had a negative trailing twelve-month return on equity of 16.16% and a negative net margin of 31.45%.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $278.00 million-$280.00 million, compared to the consensus revenue estimate of $278.63 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.28%), Artisan Partners Limited Partnership (4.12%), State Street Corp (3.55%), Fred Alger Management LLC (2.94%), Lord Abbett & CO. LLC (2.40%) and Riverbridge Partners LLC (1.29%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends
.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $46.46.

How much money does Glaukos make?

Glaukos (NYSE:GKOS) has a market capitalization of $2.22 billion and generates $294.01 million in revenue each year. The medical instruments supplier earns $-49,590,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

How many employees does Glaukos have?

The company employs 727 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.

This page (NYSE:GKOS) was last updated on 11/29/2022 by MarketBeat.com Staff